Axonal damage is a prominent feature of MS responsible for long-term disability and functional deficits in those afflicted with the disease. In this review we outlined biochemical, clinical, neuropathological, and neuroimaging evidence in support of neurodegeneration as a direct consequence of demyelination or as an independently occurring concurrent event. Future studies should continue to address the molecular changes that occur to both axons and myelin in order to determine the specific sequence of events underlying the disease pathogenesis of MS. Novel therapies addressing the neurodegenerative component of the disease may hold clues for halting its progression and promoting functional recovery in those afflicted with MS.


This work is funded in part by a grant from the National Multiple Sclerosis Foundation (NMSS RG-4134/A9) and American Recovery and Reinvestment Act Funds (R01-NS42925-07S1 and NS42925-08) to PC.



Potential conflict of interest: Nothing to report.


1. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin. 1996;14:291–308. [PubMed]
2. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938–952. [PubMed]
3. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7:268–277. [PubMed]
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269. [PubMed]
5.. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5:343–354. [PubMed]
6. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120(part 6):1085–1096. [PubMed]
7. Kornek B, Lassmann H. Axonal pathology in multiple sclerosis: a historical note. Brain Pathol. 1999;9:651–656. [PubMed]
8. Brück W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J Neurol. 2005;252(suppl 5):v10–v15. [PubMed]
9. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005;252(suppl 5):v3–v9. [PubMed]
10. De Vos KJ, Grierson AJ, Ackerley S, et al. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci. 2008;31:151–173. [PubMed]
11. Saxena S, Caroni P. Mechanisms of axon degeneration: from development to disease. Prog Neurobiol. 2007;83:174–191. [PubMed]
12. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999;2:50–56. [PubMed]
13. Koo EH, Sisodia SS, Archer DR, et al. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A. 1990;87:1561–1565. [PMC free article] [PubMed]
14. Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease. Neuromolecular Med. 2002;2:151–165. [PubMed]
15. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain. 2000;123(part 6):1174–1183. [PubMed]
16. Ferguson B, Matyszak MK, Esiri MM, et al. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120(part 3):393–399. [PubMed]
17. Watson DF, Fittro KP, Hoffman PN, et al. Phosphorylation-related immunoreactivity and the rate of transport of neurofilaments in chronic 2,5-hexanedione intoxication. Brain Res. 1991;539:103–109. [PubMed]
18. Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer’s disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res. 1996;739:79–87. [PubMed]
19. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol. 1993;86:55–64. [PubMed]
20. Wegner C, Esiri MM, Chance SA, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006;67:960–967. [PubMed]
21. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278–285. [PubMed]
22. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157:267–276. [PMC free article] [PubMed]
23. Evangelou N, Konz D, Esiri MM, et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain. 2000;123(part 9):1845–1849. [PubMed]
 24. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients [published correction appears in Brain 2007;130(part 3):879] Brain. 2006;129:3165–3172. [PubMed]
25. Bolton C, Paul C. Glutamate receptors in neuro-inflammatory demyelinating disease. Mediators Inflamm. 2006;2006:93684. [PMC free article] [PubMed]
26. Lassmann H. Recent neuropathological findings in MS–implications for diagnosis and therapy. J Neurol. 2004;251(suppl 4):IV2–IV5. [PubMed]
27. Raine CS, Cross AH. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest. 1989;60:714–725. [PubMed]
28. Irvine KA, Blakemore WF. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol. 2006;175:69–76. [PubMed]
29. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain. 2008;131(part 6):1464–1477. [PubMed]
30. Siffrin V, Vogt J, Radbruch H, et al. Multiple sclerosis: candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010;33:202–210. [PubMed]
31. Davies GR, Ramió-Torrentá L, Hadjiprocopis A, et al. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:998–1002. [PMC free article] [PubMed]
32. Ramió-Torrentá L, Sastre-Garriga J, Ingle GT, et al. Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry. 2006;77:40–45. [PMC free article] [PubMed]
33. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003;60:1157–1162. [PubMed]
34. Peterson JW, Bø L, Mørk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389–400. [PubMed]
35. Bø L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003;9:323–331. [PubMed]
36. Brink BP, Veerhuis R, Breij EC, et al. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol. 2005;64:147–155. [PubMed]
37. Agosta F, Rovaris M, Pagani E, et al. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129:2620–2627. [PubMed]
38. Fisniku LK, Chard DT, Jackson JS, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis [published correction appears in Ann Neurol 2009;65:232] Ann Neurol. 2008;64:247–254. [PubMed]
39. Fisher E, Lee JC, Nakamura K, et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol. 2008;64:255–265. [PubMed]
40. Rovaris M, Judica E, Gallo A, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain. 2006;129:2628–2634. [PubMed]
41. Manfredonia F, Ciccarelli O, Khaleeli Z, et al. Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. Arch Neurol. 2007;64:411–415. [PubMed]
42. Cifelli A, Arridge M, Jezzard P, et al. Thalamic neuro-degeneration in multiple sclerosis. Ann Neurol. 2002;52:650–653. [PubMed]
43. Huizinga R, Gerritsen W, Heijmans N, et al. Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis. 2008;32:461–470. [PubMed]
 44. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–1104. [PubMed]
45. Androdias G, Reynolds R, Chanal M, et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol. 2010;68:465–476. [PubMed]
46. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–1189. [PMC free article] [PubMed]
47. Tallantyre EC, Bø L, Al-Rawashdeh O, et al. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain. 2009;132:1190–1199. [PubMed]
48. Griffiths I, Klugmann M, Anderson T, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280:1610–1613. [PubMed]
49. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33:366–374. [PubMed]
50. Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci. 1998;18:1953–1962. [PubMed]
51. Nave KA. Myelination and the trophic support of long axons. Nat Rev Neurosci. 2010;11:275–283. [PubMed]
52. Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) Mult Scler. 1999;5:283–286. [PubMed]
53. Revesz T, Kidd D, Thompson AJ, et al. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994;117(part 4):759–765. [PubMed]
54. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991;29:53–62. [PubMed]
55. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–1438. [PubMed]
56. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46:296–304. [PubMed]
57. Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain. 2003;126:1734–1744. [PubMed]
58. Tartaglia MC, Narayanan S, Francis SJ, et al. The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol. 2004;61:201–207. [PubMed]
59. Gadea M, Martínez-Bisbal MC, Marti-Bonmatí L, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain. 2004;127:89–98. [PubMed]
60. Pan JW, Krupp LB, Elkins LE, et al. Cognitive dysfunction lateralizes with NAA in multiple sclerosis. Appl Neuropsychol. 2001;8:155–160. [PubMed]
61. Riccitelli G, Rocca MA, Pagani E, et al. Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Hum Brain Mapp. 2010 doi: 10.1002/hbm.21125. [PubMed] [Cross Ref]
62. Gold SM, Kern KC, O’Connor MF, et al. Smaller cornu ammonis 2–3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry. 2010;68:553–559. [PMC free article] [PubMed]
63. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002;122:132–139. [PubMed]
64. Kapaki E, Paraskevas GP, Michalopoulou M, et al. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol. 2000;43:228–232. [PubMed]
65. Lycke JN, Karlsson JE, Andersen O, et al. Neuro-filament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64:402–404. [PMC free article] [PubMed]
66. Malmeström C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003;61:1720–1725. [PubMed]
67. Tumani H, Hartung HP, Hemmer B, et al. BioMS Study Group. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 2009;35:117–127. [PubMed]
68. Tomassini V, Palace J. Multiple sclerosis lesions: insights from imaging techniques. Expert Rev Neurother. 2009;9:1341–1359. [PubMed]
69. Vrenken H, Geurts JJ. Gray and normal-appearing white matter in multiple sclerosis: an MRI perspective. Expert Rev Neurother. 2007;7:271–279. [PubMed]
70. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412–1420. [PubMed]
71. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999;53:1698–1704. [PubMed]
72. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage. 2008;42:315–322. [PubMed]
73. Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 2005;236:254–260. [PubMed]
74. Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain. 1999;122(part 1):17–26. [PubMed]
75. Geurts JJ, Bø L, Pouwels PJ, et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol. 2005;26:572–577. [PubMed]
76. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging. 2001;13:534–546. [PubMed]
77. Behrens TE, Johansen-Berg H, Woolrich MW, et al. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci. 2003;6:750–757. [PubMed]
78. Filippi M, Cercignani M, Inglese M, et al. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology. 2001;56:304–311. [PubMed]
79. Rovaris M, Iannucci G, Falautano M, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci. 2002;195:103–109. [PubMed]
80. Inglese M, Madelin G, Oesingmann N, et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain. 2010;133:847–857. [PMC free article] [PubMed]
81. Waxman SG. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat Rev Neurosci. 2006;7:932–941. [PubMed]
82. Arnold DL, Matthews PM, Francis G, et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990;14:154–159. [PubMed]
83. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology. 1990;40:1764–1769. [PubMed]
84. Simmons ML, Frondoza CG, Coyle JT. Immunocyto-chemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37–45. [PubMed]
85. De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy in multiple sclerosis. J Neuroimaging. 2007;17(suppl 1):10S–15S. [PubMed]
86. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65–70. [PubMed]
87. Matthews PM, De Stefano N, Narayanan S, et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol. 1998;18:327–336. [PubMed]
88. Grossman RI, Lenkinski RE, Ramer KN, et al. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol. 1992;13:1535–1543. [PubMed]
89. Matthews PM, Francis G, Antel J, et al. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published correction appears in Neurology 1991;41:1828] Neurology. 1991;41:1251–1256. [PubMed]
90. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117(part 1):49–58. [PubMed]
91. Bjartmar C, Kidd G, Mörk S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901. [PubMed]
92. Suhy J, Rooney WD, Goodkin DE, et al. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler. 2000;6:148–155. [PMC free article] [PubMed]
93. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:646–651. [PubMed]
94. Okuda DT, Srinivasan R, Oksenberg JR, et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009;132:250–259. [PMC free article] [PubMed]
95. Nicoli F, Vion-Dury J, Confort-Gouny S, et al. Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy. C R Acad Sci III. 1996;319:623–631. [PubMed]
96. Simone IL, Federico F, Trojano M, et al. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sci. 1996;144:182–190. [PubMed]
97. Fonalledas Perelló MA, Politi JV, Dallo Lizarraga MA, et al. The cerebrospinal fluid lactate is decreased in early stages of multiple sclerosis. P R Health Sci J. 2008;27:171–174. [PubMed]
98. Aasly J, Gårseth M, Sonnewald U, et al. Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. Acta Neurol Scand. 1997;95:9–12. [PubMed]
99. Gustafsson MC, Dahlqvist O, Jaworski J, et al. Low choline concentrations in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. AJNR Am J Neuroradiol. 2007;28:1306–1312. [PubMed]
100. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127:1361–1369. [PubMed]
101. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15:289–298. [PubMed]
102. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128:1016–1025. [PubMed]
103. Kim JY, Shen S, Dietz K, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci. 2010;13:180–189. [PMC free article] [PubMed]
104. Pitt D, Nagelmeier IE, Wilson HC, et al. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology. 2003;61:1113–1120. [PubMed]
105. Matute C. Oligodendrocyte NMDA receptors: a novel therapeutic target. Trends Mol Med. 2006;12:289–292. [PubMed]
106. Baranzini SE, Srinivasan R, Khankhanian P, et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain. 2010;133:2603–2611. [PMC free article] [PubMed]
107. Kiferle L, Politis M, Muraro PA, et al. Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol. 2011;18:226–231. [PubMed]
108. Schiepers C, Van Hecke P, Vandenberghe R, et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler. 1997;3:8–17. [PubMed]
109. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000;123(part 11):2321–2337. [PubMed]
110. Wilms H, Claasen J, Röhl C, et al. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis. 2003;14:417–424. [PubMed]
111. Blinkenberg M, Rune K, Jensen CV, et al. Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS. Neurology. 2000;54:558–564. [PubMed]
112. Wang Y, Wu C, Caprariello AV, et al. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci. 2009;29:14663–14669. [PMC free article] [PubMed]
113. Dziedzic T, Metz I, Dallenga T, et al. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol. 2010;20:976–985. [PubMed]
114. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy [published correction appears in Brain Pathol 2007;17:345] Brain Pathol. 2007;17:230–242. [PubMed]
115. Nicot A, Ratnakar PV, Ron Y, et al. Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain. 2003;126:398–412. [PubMed]
116. Nicot A, Kurnellas M, Elkabes S. Temporal pattern of plasma membrane calcium ATPase 2 expression in the spinal cord correlates with the course of clinical symptoms in two rodent models of autoimmune encephalomyelitis. Eur J Neurosci. 2005;21:2660–2670. [PMC free article] [PubMed]
117. Kurnellas MP, Nicot A, Shull GE, et al. Plasma membrane calcium ATPase deficiency causes neuronal pathology in the spinal cord: a potential mechanism for neurodegeneration in multiple sclerosis and spinal cord injury. FASEB J. 2005;19:298–300. [PMC free article] [PubMed]
118. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci. 2008;31:535–561. [PubMed]
119. Stys PK. White matter injury mechanisms. Curr Mol Med. 2004;4:113–130. [PubMed]
120. Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182–192. [PMC free article] [PubMed]
121. Giuliani F, Goodyer CG, Antel JP, et al. Vulnerability of human neurons to T cell-mediated cytotoxicity. J Immunol. 2003;171:368–379. [PubMed]
122. Vogt J, Paul F, Aktas O, et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol. 2009;66:310–322. [PubMed]
123. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192:393–404. [PMC free article] [PubMed]
124. Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood. 2004;103:4222–4231. [PubMed]

There are more of the above References but didn`t let me  add any more but you can see the rest on the website page I got the above information from
Close info